Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results